Cardiotoxicity of Anthracyclines and HER2 ‐Targeted Therapies: Current Insights, Predictive AI Models, Preventive Strategies, and a Proposed AI ‐Assisted Cardio‐Oncology Pathway
Cancer Reports · 2026-11 · 9 (11)
DOI: 10.1002/cnr2.70747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, online erschienen am 17.11.2026. Verfasst von Philippe Attieh und 6 weiteren Autor:innen. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Advances in hematology‐oncology have substantially improved survival among patients with cancer. However, longer survival has been accompanied by an increasing burden of cancer therapy‐related cardiovascular toxicity (CTR‐CVT), which contributes to overall morbidity and mortality among cancer survivors. Cancer therapy‐related cardiac dysfunction (CTRCD), one component of CTR‐CVT, may manifest as asymptomatic reductions in left ventricular ejection fraction (LVEF) or as severe, symptomatic heart failure, whereas myocarditis, arrhythmias, and pericardial disease represent distinct manifestations of CTR‐CVT. Outcomes may be worsened by patient‐related risk factors, such as age, obesity, diabetes mellitus, and hypertension. Predicting cardiotoxicity is therefore important for preventing adverse events, and artificial intelligence (AI)‐based models have been developed for this purpose. This narrative review focuses primarily on cardiotoxicity related to anthracyclines and human epidermal growth factor receptor 2 (HER2)‐targeted therapies, together with the risk factors specific to these two drug classes. Immune checkpoint inhibitors are discussed as a clinically relevant comparison, and fluoropyrimidines, vascular endothelial growth factor inhibitors, anaplastic lymphoma kinase inhibitors, and radiotherapy are summarized more briefly for context. Recent Findings This review examines diagnostic and monitoring tools such as echocardiography, cardiac biomarkers, and advanced imaging techniques, highlighting their strengths and limitations. Furthermore, this review critically examines AI‐based models developed to predict cardiotoxicity, with particular attention to their performance, limitations, and potential clinical applications. Although these models may improve risk stratification and support earlier identification of high‐risk patients, the available evidence remains predominantly retrospective and heterogeneous, with limited external and prospective validation.
Conclusion
By summarizing recent studies and selected preventive strategies, this review proposes a clinically oriented framework for future evaluation of AI‐assisted cardio‐oncology pathways while emphasizing that current models should complement, rather than replace, established clinical assessment and surveillance.
Zitieren
APA
Attieh, P., Hazzouri, A. A., Qassab, M. A., Sleiman, C., Skouri, H., Ghadieh, H. E., & Harbieh, B. (2026). Cardiotoxicity of Anthracyclines and HER2 ‐Targeted Therapies: Current Insights, Predictive AI Models, Preventive Strategies, and a Proposed AI ‐Assisted Cardio‐Oncology Pathway. Cancer Reports, 9(11). https://doi.org/10.1002/cnr2.70747
Vancouver
Attieh P, Hazzouri AA, Qassab MA, Sleiman C, Skouri H, Ghadieh HE, et al. Cardiotoxicity of Anthracyclines and HER2 ‐Targeted Therapies: Current Insights, Predictive AI Models, Preventive Strategies, and a Proposed AI ‐Assisted Cardio‐Oncology Pathway. Cancer Reports. 2026;9(11). doi:10.1002/cnr2.70747
BibTeX
@article{Attieh2026,
author = {Attieh, Philippe and Hazzouri, Antonio Al and Qassab, Mohamad Al and Sleiman, Christopher and Skouri, Hadi and Ghadieh, Hilda E. and Harbieh, Bernard},
title = {Cardiotoxicity of Anthracyclines and HER2 ‐Targeted Therapies: Current Insights, Predictive AI Models, Preventive Strategies, and a Proposed AI ‐Assisted Cardio‐Oncology Pathway},
journal = {Cancer Reports},
year = {2026},
volume = {9},
number = {11},
doi = {10.1002/cnr2.70747}
}
EUVIMED